The IMID Forum

EXPLORE

Society & Culture

© 2024 PodJoint

https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/a8/bf/5d/a8bf5df6-8cd2-a187-e5c3-60a7f75db2e3/mza_8088200508660774341.jpg/600x600bb.jpg

The IMID Forum

The Immune-Mediated Inflammatory Disease Forum

384 episodes

14 hours ago

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.

Show more...

All content for The IMID Forum is the property of The Immune-Mediated Inflammatory Disease Forum and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.

Show more...

Episodes (20/384)

The IMID Forum

Discussing RA: Real-world evaluation of JAKi efficacy, persistence, and cardiovascular safety in RA

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.

14 hours ago

9 minutes 45 seconds

The IMID Forum

Author Interview: Professor Filip Rob, 2025

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Filip Rob, the Department of head of the Dermatovenereology at the Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic, as they discuss his recent paper ‘Efficacy, safety, and drug survival during the first year of biologic therapy for psoriasis in elderly versus younger patients’.

1 week ago

25 minutes 7 seconds

The IMID Forum

Webinar Highlights: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs: Part 2

Webinar highlights! Join Professor Iain McInnes and Drs Grace Wright and Melinda Gooderham as they discuss advancing patient care through an interdisciplinary approach to IMIDs. This webinar provides information on bridging care pathways, advancing IMID treatment, and case studies of interdisciplinary care.

1 week ago

17 minutes 2 seconds

The IMID Forum

Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.

2 weeks ago

14 minutes 37 seconds

The IMID Forum

Discussing RA: Long-term management of elderly patients with RA treated with tocilizumab

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, Iain will review a paper by B Fautrel, in which authors compare patient characteristics and long-term management with tocilizumab in RA patients over and under 75 years of age, and tolerance of RA treatments.

3 weeks ago

5 minutes 15 seconds

The IMID Forum

ACR 2025 Review Podcast

Join Doctor Sofia Ramiro and Professors Janet Pope and Atul Deodhar, as they review and discuss key data from ACR 2025 across RA, PsA, and axSpA, focusing on implications for clinical practice.

3 weeks ago

40 minutes 15 seconds

The IMID Forum

ACR Daily Highlights Day 4

Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 4 of ACR 2025 (Wednesdsy, 29th of October)

4 weeks ago

1 minute 48 seconds

The IMID Forum

ACR Daily Highlights: Day 3

Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 3 of ACR 2025 (Tuesday 28th of October)

1 month ago

3 minutes 49 seconds

The IMID Forum

Pathways Modulating IMIDs: Webinar Highlights Podcast

Professors Janet Pope and John Isaacs discuss all the highlights from the 'Pathways Modulating IMIDs' webinar.

1 month ago

24 minutes 49 seconds

The IMID Forum

ACR Daily Highlights: Day 2

Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 2 of ACR 2025 (Monday, 27th of October)

1 month ago

4 minutes 3 seconds

The IMID Forum

ACR Daily Highlights: Day 1

Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of ACR 2025 (Sunday, 26th of October)

1 month ago

3 minutes 49 seconds

The IMID Forum

ACR 2025 Preview Podcast

Join Professors Peter Nash, Janet Pope and Atul Deodhar as they preview what they are most looking forward to this ACR, introducing some of the top chosen abstracts and posters in RA, AxSpA and PsA so that you can better plan your time at what will be a busy and exciting congress. #ACR2025

1 month ago

22 minutes 47 seconds

The IMID Forum

Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’.

1 month ago

18 minutes 31 seconds

The IMID Forum

Author Interview: Doctor David Kellner, September 2025

Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor David Kellner, an IGNITE-MSCR Fellow of the Division of Rheumatology, from UCLA Medical Centre, LA, USA, as they discuss his recent review ‘Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis’.

1 month ago

22 minutes 44 seconds

The IMID Forum

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he highlights two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.

2 months ago

8 minutes 44 seconds

The IMID Forum

Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the effectiveness of ixekizumab in real-world patients with axSpA and PsA, and the real‑world comparison of clinical effectiveness of UPA, TNF inhibitors or IL‑17 inhibitors in patients with axSpA after switching from an initial TNF inhibitor.

2 months ago

20 minutes 52 seconds

The IMID Forum

Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis

Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month’s discussion covered the ‘Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis’. Read the full paper summary online at www.imidforum.com.

2 months ago

7 minutes 41 seconds

The IMID Forum

Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

Join Professor Peter Nash from Griffith University in Brisbane, and Dr Rodrigo Garcia‑Salinas from Hospital Italiano de La Plata in Argentina, as they discuss Dr Garcia-Salinas’ recent publication ‘Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns’.

3 months ago

28 minutes 57 seconds

The IMID Forum

Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

Join Professor Peter Nash from the Griffith University in Brisbane, and authors Dr Martin Schaefer from the German Rheumatology Research Center in Berlin, Germany and Professor Anja Strangfeld, the head of epidemiology at the German Rheumatology Research Centre. In this episode they discuss a recent study from the German RABBIT registry, investigating the comparative risk of malignancies in rheumatoid arthritis patients treated with JAK inhibitors versus bDMARDs.

3 months ago

45 minutes 23 seconds

The IMID Forum

Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA’ and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab’.

3 months ago

17 minutes 45 seconds